<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ANTISEDAN- atipamezole hydrochloride injection, solution </strong><br>Zoetis Inc.<br></p></div>
<h1>ANTISEDAN<span class="Sup">®</span><br> (atipamezole hydrochloride)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Italics">Sterile Injectable Solution - 5.0 mg/mL</span></p>
<p><span class="Italics">Dexmedetomidine and Medetomidine Reversing Agent</span></p>
<p><span class="Italics">For intramuscular use in dogs only</span></p>
<p>NADA #141-033, Approved by FDA</p>
</div>
<div class="Section" data-sectionCode="50741-8">
<a name="section-2"></a><p></p>
<p class="First"><span class="Bold">CAUTION:</span> Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-3"></a><p></p>
<p class="First"><span class="Bold">DESCRIPTION:</span> ANTISEDAN (atipamezole hydrochloride) is a synthetic α<span class="Sub">2</span>-adrenergic antagonist.  </p>
<p>The chemical name is 4-(2-ethyl-2,3-dihydro-1H-inden-2-yl)-1H-imidazole hydrochloride.</p>
<p>The molecular formula is C<span class="Sub">14</span>H<span class="Sub">16</span>N<span class="Sub">2</span> • HCl and structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=403065e1-4c1a-433c-bb1b-6a2951946297&amp;name=antisedan-01.jpg"></div>
<p>Each mL of ANTISEDAN contains 5.0 mg atipamezole hydrochloride, 1.0 mg methylparaben (NF), 8.5 mg sodium chloride (USP), and water for injection (USP).</p>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="section-4"></a><p></p>
<p class="First"><span class="Bold">INDICATIONS:</span> ANTISEDAN is indicated for the reversal of the sedative and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> of DEXDOMITOR (dexmedetomidine hydrochloride), and DOMITOR (medetomidine hydrochloride) in dogs.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-5"></a><p></p>
<p class="First"><span class="Bold">DOSAGE AND ADMINISTRATION:</span> ANTISEDAN is administered intramuscularly (IM) for reversal of sedation and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> regardless of the route used for DEXDOMITOR or DOMITOR. The atipamezole dose for the reversal of IV DEXDOMITOR or DOMITOR is 3750 mcg/m<span class="Sup">2</span>. The atipamezole dose for the reversal of IM DEXDOMITOR or DOMITOR is 5000 mcg/m<span class="Sup">2</span>.</p>
<p>The dosage of ANTISEDAN is calculated based on body surface area. Use the following tables to determine the correct injection volume or the correct ANTISEDAN dosage on the basis of kilograms of body weight.</p>
<p><span class="Bold">Note that the mcg/kg dosage decreases as body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight increases</span>.</span></p>
<table width="80%">
<caption><span>Table 1: Atipamezole dosing for reversal of IV dexmedetomidine- or medetomidine-induced sedation/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>:</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="40%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="4">Dose table for ANTISEDAN (3750 mcg/m<span class="Sup">2</span>) when dexmedetomidine or medetomidine is given IV</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">For # lbs</th>
<th class="Rrule" align="center">For # kg</th>
<th class="Rrule" align="center">dose = mcg/kg</th>
<th class="Rrule" align="center">volume = mL ANTISEDAN</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">  4-7</td>
<td class="Rrule" align="center">2-3</td>
<td class="Rrule" align="center">300</td>
<td class="Rrule" align="center">0.1  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  7-9</td>
<td class="Rrule" align="center">3-4</td>
<td class="Rrule" align="center">250</td>
<td class="Rrule" align="center">0.15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  9-11</td>
<td class="Rrule" align="center">4-5</td>
<td class="Rrule" align="center">230</td>
<td class="Rrule" align="center">0.2  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  11-22</td>
<td class="Rrule" align="center">5-10</td>
<td class="Rrule" align="center">200</td>
<td class="Rrule" align="center">0.3  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  22-33</td>
<td class="Rrule" align="center">10-15</td>
<td class="Rrule" align="center">170</td>
<td class="Rrule" align="center">0.4  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  33-44</td>
<td class="Rrule" align="center">15-20</td>
<td class="Rrule" align="center">150</td>
<td class="Rrule" align="center">0.5  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  44-55</td>
<td class="Rrule" align="center">20-25</td>
<td class="Rrule" align="center">140</td>
<td class="Rrule" align="center">0.6  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  55-66</td>
<td class="Rrule" align="center">25-30</td>
<td class="Rrule" align="center">130</td>
<td class="Rrule" align="center">0.7  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  66-81</td>
<td class="Rrule" align="center">30-37</td>
<td class="Rrule" align="center">120</td>
<td class="Rrule" align="center">0.8  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  81-99</td>
<td class="Rrule" align="center">37-45</td>
<td class="Rrule" align="center">110</td>
<td class="Rrule" align="center">0.9  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  99-110</td>
<td class="Rrule" align="center">45-50</td>
<td class="Rrule" align="center">105</td>
<td class="Rrule" align="center">1.0  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  110-132</td>
<td class="Rrule" align="center">50-60</td>
<td class="Rrule" align="center">100</td>
<td class="Rrule" align="center">1.1  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  132-143</td>
<td class="Rrule" align="center">60-65</td>
<td class="Rrule" align="center">95</td>
<td class="Rrule" align="center">1.2  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  143-165</td>
<td class="Rrule" align="center">65-75</td>
<td class="Rrule" align="center">93</td>
<td class="Rrule" align="center">1.3  </td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  165-176</td>
<td class="Rrule" align="center">75-80</td>
<td class="Rrule" align="center">91</td>
<td class="Rrule" align="center">1.4  </td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  &gt;176</td>
<td class="Rrule" align="center">&gt;80</td>
<td class="Rrule" align="center">90</td>
<td class="Rrule" align="center">1.5  </td>
</tr>
</tbody>
</table>
<table width="80%">
<caption><span>Table 2: Atipamezole dosing for reversal of IM dexmedetomidine- or medetomidine-induced sedation/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>:</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="40%">
<thead>
<tr class="Botrule First"><th class="Lrule Rrule" align="center" colspan="4">Dose table for ANTISEDAN (5000 mcg/m<span class="Sup">2</span>) when dexmedetomidine or medetomidine is given IM</th></tr>
<tr class="Last">
<th class="Lrule Rrule" align="left">For # lbs</th>
<th class="Rrule" align="center">For # kg</th>
<th class="Rrule" align="center">dose = mcg/kg</th>
<th class="Rrule" align="center">volume = mL ANTISEDAN</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left">  4-7</td>
<td class="Rrule" align="center">2-3</td>
<td class="Rrule" align="center">400</td>
<td class="Rrule" align="center">0.15</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  7-9</td>
<td class="Rrule" align="center">3-4</td>
<td class="Rrule" align="center">350</td>
<td class="Rrule" align="center">0.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  9-11</td>
<td class="Rrule" align="center">4-5</td>
<td class="Rrule" align="center">300</td>
<td class="Rrule" align="center">0.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  11-22</td>
<td class="Rrule" align="center">5-10</td>
<td class="Rrule" align="center">250</td>
<td class="Rrule" align="center">0.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  22-29</td>
<td class="Rrule" align="center">10-13</td>
<td class="Rrule" align="center">230</td>
<td class="Rrule" align="center">0.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  29-33</td>
<td class="Rrule" align="center">13-15</td>
<td class="Rrule" align="center">210</td>
<td class="Rrule" align="center">0.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  33-44</td>
<td class="Rrule" align="center">15-20</td>
<td class="Rrule" align="center">200</td>
<td class="Rrule" align="center">0.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  44-55</td>
<td class="Rrule" align="center">20-25</td>
<td class="Rrule" align="center">180</td>
<td class="Rrule" align="center">0.8</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  55-66</td>
<td class="Rrule" align="center">25-30</td>
<td class="Rrule" align="center">170</td>
<td class="Rrule" align="center">0.9</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  66-73</td>
<td class="Rrule" align="center">30-33</td>
<td class="Rrule" align="center">160</td>
<td class="Rrule" align="center">1.0</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  73-81</td>
<td class="Rrule" align="center">33-37</td>
<td class="Rrule" align="center">150</td>
<td class="Rrule" align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  81-99</td>
<td class="Rrule" align="center">37-45</td>
<td class="Rrule" align="center">145</td>
<td class="Rrule" align="center">1.2</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  99-110</td>
<td class="Rrule" align="center">45-50</td>
<td class="Rrule" align="center">140</td>
<td class="Rrule" align="center">1.3</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  110-121</td>
<td class="Rrule" align="center">50-55</td>
<td class="Rrule" align="center">135</td>
<td class="Rrule" align="center">1.4</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  121-132</td>
<td class="Rrule" align="center">55-60</td>
<td class="Rrule" align="center">130</td>
<td class="Rrule" align="center">1.5</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  132-143</td>
<td class="Rrule" align="center">60-65</td>
<td class="Rrule" align="center">128</td>
<td class="Rrule" align="center">1.6</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  143-154</td>
<td class="Rrule" align="center">65-70</td>
<td class="Rrule" align="center">125</td>
<td class="Rrule" align="center">1.7</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">  154-176</td>
<td class="Rrule" align="center">70-80</td>
<td class="Rrule" align="center">123</td>
<td class="Rrule" align="center">1.8</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left">  &gt;176</td>
<td class="Rrule" align="center">&gt;80</td>
<td class="Rrule" align="center">120</td>
<td class="Rrule" align="center">1.9</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<p class="First"><span class="Bold">CONTRAINDICATIONS:</span> Since atipamezole is always used concomitantly with dexmedetomidine or medetomidine, it should not be used in dogs with the following conditions: cardiac disease, <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span>, liver or kidney diseases, dogs in <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, severely debilitated dogs, or dogs stressed due to extreme heat, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<p>Administration of atipamezole is contraindicated in dogs with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<p class="First"><span class="Bold">HUMAN WARNINGS:</span> Not for human use. Keep out of reach of children.</p>
<p>Atipamezole hydrochloride can be absorbed and may cause irritation following direct exposure to skin, eyes, or mouth. In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing.</p>
<p>If irritation or other adverse reaction occurs (for example, increased heart rate, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>), seek medical attention.</p>
<p>In case of accidental oral exposure or injection, seek medical attention. Caution should be used while handling and using filled syringes. Users with cardiovascular disease (for example, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">ischemic heart disease</span>) should take special precautions to avoid any exposure to this product.</p>
<p>The material safety data sheet (MSDS) contains more detailed occupational safety information.</p>
<p>To report adverse reactions in users or to obtain a copy of the MSDS for this product call 1-888-963-8471.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Note to Physician:</span> This product contains an alpha<span class="Sub">2</span>-adrenergic antagonist.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<p class="First"><span class="Bold">PRECAUTIONS:</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">1. Handling:</span> ANTISEDAN can produce an abrupt reversal of sedation; therefore, dogs that have recently received ANTISEDAN should be handled with caution. The potential for apprehensive or <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive behavior</span> should be considered in the handling of dogs emerging from sedation, especially in dogs predisposed to <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> or fright. Also, avoid situations where a dog might <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">2. Sedation relapse:</span> While atipamezole does reverse the clinical signs associated with medetomidine or dexmedetomidine sedation, complete physiologic return to pretreatment status may not be immediate or may be temporary, and dogs should be monitored for sedation relapse. Sedation relapse is more likely to occur in dogs that receive an alpha<span class="Sub">2</span>-agonist by the IV route, compared to dogs that are sedated using the IM route. Animals should be monitored closely for persistent <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, and depressed respiration, until signs of recovery persist.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<p class="First"><span class="Bold">3. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> reversal:</span> Atipamezole reverses <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> as well as sedative effects. Additional procedures for the control of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> may be required.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4"></a><p></p>
<p class="First"><span class="Bold">4. Debilitated dogs:</span> The safety of atipamezole has not been evaluated in dogs with compromised health. Geriatric, debilitated, and ill dogs are more likely to experience adverse reactions associated with the administration of alpha<span class="Sub">2</span>-antagonists (as well as alpha<span class="Sub">2</span>-agonists). Dogs with abnormalities associated with the cardiovascular system are especially at risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<p class="First"><span class="Bold">5. Breeding dogs:</span> ANTISEDAN has not been evaluated in breeding dogs; therefore, the drug is not recommended for use in pregnant or lactating dogs, or in dogs intended for breeding.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6"></a><p></p>
<p class="First"><span class="Bold">6. Minimum age and weight:</span> ANTISEDAN has not been evaluated in dogs less than four months of age or in dogs weighing less than 4.4 lbs (2 kg).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<p class="First"><span class="Bold">ADVERSE REACTIONS:</span> Occasional <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> may occur. At times, a period of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> or apprehensiveness may be seen in dogs treated with atipamezole. Other effects of atipamezole include <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">hypersalivation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-10"></a><p></p>
<p class="First"><span class="Bold">CLINICAL PHARMACOLOGY:</span> Atipamezole is a potent alpha<span class="Sub">2</span>-antagonist which selectively and competitively inhibits alpha<span class="Sub">2</span>-adrenergic receptors. The result of atipamezole administration in the dog is the rapid recovery from the sedative and <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effects</span> produced by the alpha<span class="Sub">2</span>-adrenergic agonists dexmedetomidine or medetomidine. Atipamezole does not reverse the effects of other classes of sedatives, anesthetics, or analgesics.</p>
<p>Atipamezole is rapidly absorbed following intramuscular injection; maximum serum concentration is reached in approximately 10 minutes. Onset of arousal is usually apparent within 5 to 10 minutes of injection, depending on the depth and duration of dexmedetomidine- or medetomidine-induced sedation. Elimination half-life from serum is less than 3 hours. Atipamezole undergoes extensive hepatic biotransformation, with excretion of metabolites primarily in urine.</p>
<p>Dexmedetomidine or medetomidine activation of peripheral and central alpha<span class="Sub">2</span>-adrenergic receptors induces a pattern of pharmacological responses that include sedation, reduction of <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.</p>
<p>Blood pressure is initially increased due to <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">peripheral vasoconstriction</span> and thereafter drops to normal or slightly below normal levels. A transient, decrease in systolic blood pressure occurs immediately after administration of atipamezole to dexmedetomidine- or medetomidine-sedated dogs, followed by a transient increase in arterial pressure within 10 minutes compared to pre-atipamezole levels. This is the opposite of the response to alpha<span class="Sub">2</span>-agonist treatment, and is probably due to atipamezole-induced peripheral vasodilation.</p>
<p>Atipamezole administration rapidly abolishes dexmedetomidine- or medetomidine-induced <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, usually within 3 minutes. The magnitude of the effect of atipamezole on heart rate is greater when dexmedetomidine is administered intravenously compared to intramuscularly. Dogs receiving medetomidine or IM dexmedetomidine may not return to pre-sedative heart rates after atipamezole administration and some dogs briefly show heart rate elevations above baseline. <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">Respiratory rate</span> increases following atipamezole injection.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11"></a><p></p>
<p class="First"><span class="Bold">EFFECTIVENESS:</span> One hundred and nine dogs received atipamezole in the field study (55 dogs received the reversal agent following dexmedetomidine; 54 following medetomidine). The mean age was 5.9 years and ranged between 17 weeks and 16 years. The mean weight was 45.5 lbs (20.7 kg), ranging from 4.8 lbs to 117 lbs (2.2 kg to 53.2 kg). Atipamezole was administered by the IM route of administration, within a range of 39-57 minutes after administration of either dexmedetomidine (IV and IM) or medetomidine (IV and IM).</p>
<p>Atipamezole reversed the effects of dexmedetomidine and medetomidine in all cases. In dexmedetomidine treated dogs, the onset of reversal was evident within 5 minutes after administration of atipamezole (57% could stand). Within 15 minutes, 96% of dexmedetomidine treated dogs were standing, 92% responded normally to sound, 86% had a normal muscle tone of jaw, and &gt;90% had a normal pedal reflex response. Responses in dogs treated with medetomidine were similar or slightly later.</p>
<p>Following atipamezole, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span> between 0 and 5 minutes following either alpha<span class="Sub">2</span>-agonist (IV dexmedetomidine dogs had heart rates from 60 to 85 bpm, and IV medetomidine dogs from 51 to 67 bpm; IM dexmedetomidine dogs had heart rates from 45 to 73 bpm, and IM medetomidine dogs from 52 to 79 bpm). <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> resolved more slowly in the IM treatment groups. The body temperature remained at the same level during the 120 minutes of follow-up after atipamezole administration. <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">Respiratory rates</span> increased toward normal between 0 and 5 minutes after the administration of atipamezole in all treatment groups. Mucous membranes were described as normal after 5 minutes in 91% of dexmedetomidine dogs (IV or IM). By 120 minutes, 96% were normal (after IV dexmedetomidine) or 100% were normal (after IM dexmedetomidine). Many physiological responses were slightly slower to return toward normal when dogs were treated with medetomidine IV or IM.</p>
<p>No adverse events were reported in the atipamezole treated dogs.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First"><span class="Bold">ANIMAL SAFETY:</span> Atipamezole was tolerated in healthy dogs receiving 10X the recommended dose and in dogs receiving repeated doses at 1, 3, and 5X the recommended dose, in the absence of an alpha<span class="Sub">2</span>-agonist. Signs were dose-related and included <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, panting, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">trembling</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, soft or liquid feces and scleral injection. At 10X the recommended dose, increases in creatine kinase, AST, and ALT were noted. Creatine kinase also increased in 3 (of 6) dogs in the 3X treatment group. Localized skeletal <span class="product-label-link" type="condition" conceptid="4048093" conceptname="Hamstring injury">muscle injury</span> was seen at the injection site but no associated clinical signs or complications were observed. Dogs receiving the recommended atipamezole dose in the absence of medetomidine or dexmedetomidine exhibited no adverse clinical signs. In additional safety studies, adverse events were absent up to the 3X dose of atipamezole when its administration followed medetomidine or dexmedetomidine sedation.</p>
<p>In a separate safety study using a crossover design, 5 dogs received atipamezole after dexmedetomidine (IV and IM). Dexmedetomidine's effects on blood pressure, heart rate, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, and cardiac conduction times were reversed by atipamezole. However, heart rate and cardiac conduction times did not return to predexmedetomidine values. Heart rate increases after atipamezole were closer to baseline values in dogs treated with dexmedetomidine IV (compared to IM).</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13"></a><p></p>
<p class="First"><span class="Bold">STORAGE INFORMATION:</span> Store protected from light at controlled room temperature 15°–30°C (59°–86°F).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-14"></a><p></p>
<p class="First"><span class="Bold">HOW SUPPLIED:</span> ANTISEDAN is supplied in 10-mL, multidose vials containing 5.0 mg of atipamezole hydrochloride per mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15"></a><p></p>
<p class="First">Antisedan<span class="Sup">®</span>, Dexdomitor<span class="Sup">®</span>, and Domitor<span class="Sup">®</span> are trademarks of Orion Corporation.</p>
<div class="Figure"><img alt="Figure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=403065e1-4c1a-433c-bb1b-6a2951946297&amp;name=antisedan-02.jpg"></div>
<p>Revised: April 2014</p>
<p>Developed and manufactured by:<br><span class="Bold">ORION<br> PHARMA<br> Orion Corporation<br></span> Espoo, Finland</p>
<p>Distributed by:<br>Zoetis Inc.<br>Kalamazoo, MI 49007</p>
<p>Made in Finland</p>
<p>107237US-6</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton</h1>
<p class="First"><span class="Bold">ORION<br> PHARMA</span></p>
<p><span class="Bold">Net Contents: 10 mL</span></p>
<p><span class="Bold">ANTISEDAN</span><span class="Sup">®</span><br><span class="Bold Italics">(atipamezole hydrochloride)</span></p>
<p><span class="Bold Italics">Sterile Injectable Solution - 5.0 mg/mL</span><br><span class="Italics">Dexmedetomidine and Medetomidine Reversing Agent</span></p>
<p>For intramuscular use in dogs only<br><span class="Bold">Caution: </span>Federal law restricts this drug to use by or on<br>the order of a licensed veterinarian.</p>
<p>NADA #141-033, Approved by FDA</p>
<p><span class="Bold Italics">zoetis</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=403065e1-4c1a-433c-bb1b-6a2951946297&amp;name=antisedan-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ANTISEDAN 		
					</strong><br><span class="contentTableReg">atipamezole hydrochloride injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54771-6293</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>atipamezole hydrochloride</strong> (atipamezole) </td>
<td class="formItem">atipamezole hydrochloride</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem">8.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54771-6293-1</td>
<td class="formItem">10 mL in 1 VIAL, GLASS</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141033</td>
<td class="formItem">08/06/1966</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Zoetis Inc.
							(828851555)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Orion Corporation (539763727)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Orion Corporation, Orion Pharma</td>
<td class="formItem"></td>
<td class="formItem">539763727</td>
<td class="formItem">API MANUFACTURE, MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>08e426e1-d3af-46ca-a7c8-d34de5356589</div>
<div>Set id: 403065e1-4c1a-433c-bb1b-6a2951946297</div>
<div>Version: 2</div>
<div>Effective Time: 20141217</div>
</div>
</div> <div class="DistributorName">Zoetis Inc.</div></p>
</body></html>
